6.6. prognostic models. prognostic models combining independent prognostic factors developed externally validated [247-254]. models accurate tnm stage grade alone predicting clinically relevant oncological outcomes (le: 3). adopted, new prognostic models evaluated compared current prognostic models regards discrimination, calibration net benefit. pathological prognostic factors used leibovich 2003 score/groups clear cell . prognostic models non-clear cell rcc, like venuss score papillary rcc . although validated several studies showed superior discrimination prognostic models, molecular markers needed [255-258]. metastatic disease, risk groups assigned memorial sloan kettering cancer centre (mskcc) (primarily created pre-targeted therapy era validated patients receiving targeted therapy) imdc (initially created targeted therapy era) differ 23% cases . imdc model used recent rcts, including immune checkpoint inhibitors (icis), may therefore preferred model clinical practice. discrimination imdc models improves additional variables, presence brain metastasis, bone metastasis, liver metastasis, nlr platelet count [260-263]. tables 6.3 6.4 summarise current relevant prognostic models.